Trending

Hong Kong

Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bid

Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bid

China’s Henlius Biotech has pressed go on a $477 million initial public offering (IPO) on the Hong Kong

X

Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bid

https://pharmaphorum.com/news/henlius-biotech-shrugs-off-hong-kong-disruption-with-477m-ipo-bid/

Hong Kong biotechs IPOs face lower valuations after Ascletis flop

Hong Kong biotechs IPOs face lower valuations after Ascletis flop

Biotechs taking an advantage of new Hong Kong exchange rules have been told to expect lower valuations, after

X

Hong Kong biotechs IPOs face lower valuations after Ascletis flop

https://pharmaphorum.com/news/hong-kong-biotech-ipos-face-lower-valuations-after-ascletis-flop/

Regulatory timelines in the Asia-Pacific

Regulatory timelines in the Asia-Pacific

Snapshot of clinical trial application processes in the region.

X

Regulatory timelines in the Asia-Pacific

https://pharmaphorum.com/views-and-analysis/regulatory-timelines-asia-pacific/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com